Trial Profile
A Multi-center, Randomized, Controlled Trial of Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary) ; Antipsychotics
- Indications Schizoaffective disorder; Schizophrenia; Substance-related disorders
- Focus Therapeutic Use
- 18 Mar 2024 Status changed from recruiting to completed.
- 12 May 2023 Planned End Date changed from 19 Sep 2023 to 19 Mar 2025.
- 12 May 2023 Planned primary completion date changed from 19 Mar 2023 to 19 Oct 2024.